The ELEVATE Study shows that atogepant effectively prevents episodic migraine.

Published Date: 24 Apr 2023

Atogepant (Qulipta) performed better than a placebo in the ELEVATE study for preventing episodic migraine in patients who were resistant to other treatments.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Dasatinib Fails to Improve Outcomes in CBF-AML

2.

Discovery of estrogen receptor 'switches' may aid breast cancer treatment

3.

Medical debt in collections persists after cancer diagnosis

4.

Childhood cancer survivors face new health problems later in life, study shows

5.

A Lot Can Be Said About You by Including Yourself in Photos.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot